This conference has already taken place. For information on the 2010 event, please click on the link below:
COPD: Novel Therapeutics and Management Strategies 2010
For information about the 2007 Asthma & COPD conference, please see below...
OUR EXPERT PANEL OF SPEAKERS INCLUDES:
• Dr Chris Compton, Executive Director Clinical R&D, Pfizer
• Dr Craig S. Conoscenti, Senior Associate Director, Medical Affairs, Boehringer-Inglehiem
• Dr Malcolm Johnson, Global Director, Respiratory Science, GlaxoSAE Media GroupthKline
• Dr Sandy Goldman, Director, Respiratory Disease, Inflammation, Wyeth
• Stephen Stenglein, Clinical & Regulatory Affairs, Novartis
• Theodore Reiss, Executive Director, Respiratory & Allergy, Merck
• Thomas Eichholtz, Director of Discovery Medicine, Respiratory & Inflammation Research Area, AstraZeneca
• Dr Fred Bode, Associate Clinical Director, F. Hoffmann-La Roche
• Dr Kevin Bacon, Founder, CSO and Head of Research & Development, Actimis Pharmaceuticals
• Dr Christopher Molloy, Senior Research Fellow & Team Leader, Inflammation & Pulmonary Disease, Johnson & Johnson
• Dr Mick Hunter, Director of Drug Discovery, Oxagen
• Dr Shahin Sanjar, Senior Director Respiratory Sciences, Altana
• Dr Woodruff Emlen, CEO, Taligen Therapeutics
• Dr Göran Tornling, Vice President & Chief Medical Officer, Biolipox
• Dr Paolo Renzi, Chief Scientific Officer, Topigen Pharmaceuticals
• Peter Kiener D.Phil, Senior Vice President, Research, MedImmune
• Dr Charles R Penn, Chief Operating Officer, Syntaxin
The conference will be chaired by;
• Dr Michael Rudolf, Consultant Respiratory Physician, Ealing Hospital and Past Chairman, British Thoracic Society COPD Consortium
• Neil Barnes, Consultant Respiratory Physician, Barts & The London NHS Trust
If you attend one respiratory conference this year this should be the one! Nowhere else will you find such a diverse speaker line- up, mix of topics and in-depth coverage of the industry!
BENEFITS OF ATTENDING ASTHMA & COPD
GAIN a valuable insight into the current pipeline developments in the respiratory arena
IDENTIFY new drug developments and concepts
REVIEW the clinical endpoints that are currently being accepted
EXAMINE the development and use of biomarkers in Asthma & COPD
HEAR case studies from the world leaders in respiratory drug discovery
WHO SHOULD ATTEND ASTHMA AND COPD
You should attend this conference if you are an Executive, Director or scientist working in the pharmaceutical or biotech industries within:
|
|
|
- Clinical & Regulatory Affairs
|
|
|
|
|
|
|
|
|
WHO WILL YOU MEET AT ASTHMA & COPD?
A sample of the companies already in attendance includes:
|
|
|
- Almiral
Conference agenda
Welcome and introductions Regulation of inflammatory genes - Drivers of inflammation in severe asthma and COPD
- Key regulatory pathways
Steroid insensitivity in severe Asthma & COPD - Why are steroids ineffective in severe asthma?
- Molecular mechanisms underlying steroid insensitivity in COPD
New therapeutic strategies - Add-on therapies to improve steroid action
- Potential monotherapies targeting regulatory pathways
Discussion and questions – review of the session Close of Executive Briefing Chairman's Opening Remarks Michael Rudolf, Chairman, British Thoracic Society Michael Rudolf, Consultant Respiratory Physician and Past Chairman British Thoracic Society COPD Consortium, Ealing Hospital THE GLOBAL ASTHMA AND COPD MARKET Dr Craig Conoscenti, Senior Associate Director, Medical Affairs, Boehringer Ingelheim Increased disease awareness Pediatric asthma sector Ageing population susceptible to COPD Treatment cost analysis ANALYZING THE CURRENT AND FUTURE TRENDS Paljit Mudhar, Industry Analyst, Frost and Sullivan - The story so far
- Market Challenges
- Drivers
- Main players
- What’s next (technologies / competition)
DEVELOPMENT AND PRECLINICAL CHARACTERIZATION Dr Sandy Goldman, Director, Respiratory Disease, Inflammation, Wyeth Rationale for targeting IL-13 in Asthma Development of a humanized neutralizing antibody against IL-13 Preclinical testing of anti-IL-13 therapy in models of respiratory disease SMALL MOLECULE CRTH2 ANTAGONISTS AS Kevin Bacon, Founder, Chief Scientific Officer & Head, Research & Development, Actimis Pharmaceuticals An overview of the role of CRTH2 in allergy and immunity Small molecule antagonists to CRTH2; Challenges of chemistry In vivo efficacy of CRTH2 antagonists in animal models of allergic disease Pre-clinical and clinical development of CRTH2 antagonists - Biophysical Aspects of Lung deposition of inhaled Aerosols
- Patients' Breathing: Deposition not only depends on particle size
- Targeting of Drugs to different lung regions
- Pulmonary Drug Delivery in Asthma and COPD
- Benefits of controlled inhalation through the drug development process
Axel Fischer, Managing Director, Activaero Gerhard Scheuch, Chief Executive Officer, Activaero ROLE OF LEUKOCYTE PROTEASES IN RESPIRATORY DISEASES Chris Molloy, Sr. Research Fellow and Team Leader, Inflammation & Pulmonary Diseases, Johnson & Johnson APPLYING ANTISENSE TO THE THERAPY OF ASTHMA AND COPD Dr Paolo Renzi, Chief Scientific Officer, Topigen Pharmaceuticals Inc - Administration and cellular uptake of oligonucleotides in the lungs
- Rationale for using a multitarget approach in asthma and COPD
- Preclinical results with TPI-ASM8 and TPI-1100
- Results with TPI-ASM8 in humans
SUPPRESSING MUCUS DEVELOPMENT IN RESPIRATORY DISEASE Dr Charles R Penn, Chief Operating Officer, Syntaxin - Role of mucus in respiratory disease
- Mechanisms for mucus production
- A protein pharmacophore that inhibits cell secretion
- Inhibition of mucus production
- Summary and conclusions
AIRWAY REMODELING IN PULMONARY FIBROSIS Professor Geoffrey Laurent, Director, Centre For Respiratory Research EMERGING NOVEL TREATMENTS Dr Woodruff Emlen, CEO, Taligen Therapeutics - Review of the role of complement in inflammation
- Therapeutic approaches to controlling complement activation
- Role of complement in asthma
- New therapeutics for asthma
Dr Chris Compton, Executive Director Clinical R & D, Pfizer Dr Chris Compton, Executive Director Clinical R & D, Pfizer Chairman’s Closing Remarks and Close of Day One Chairman's Opening Remarks Neil Barnes, Consultant Respiratory Physician, Barts & The London NHS Trust REDUCING MORTALITY IN COPD Dr Malcolm Johnson, Global Director, Respiratory Science, Respiratory Medicines Development Centre, GlaxoSmithKline - COPD is the only chronic disease where the incidence is increasing and is predicted to be the third cause of mortality by 2020
- COPD is both an airways and a systemic disease, associated with co-morbidities.
- To date, only non-pharmacological interventions (eg smoking cessation, LTOT) have been shown to reduce mortality in COPD
- Data from the TORCH and INSPIRE studies indicate that Seretide (LABA/ICS combination therapy) provides a survival benefit in COPD patients
- The underlying mechanisms of this effect may provide insights into future targets to improve the mortality risk in COPD
DEVELOPMENT AND USE OF BIOMARKERS IN ASTHMA & COPD TO HELP ACCELERATE DRUG DEVELOPMENT - Biomarkers can accelerate early Stop/Go decisions in Asthma & COPD
- Biomarkers are also important in predicting long term outcomes with short term studies
- Disease modification remains a long term challenge in both Asthma and COPD and new insights from biomarkers can help determine new therapeutic strategies
- Biomarkers remain important tools for diseases segmentation, reclassification and patient stratification in both Asthma & COPD
- Examples of such strategies will be presented during the conference
Dr Harsukh Parmar, Director, Global Discovery Medicine, Respiratory & Inflammation Therapy Area, AstraZeneca Dr Thomas Eichholtz, Director of Discovery Medicine, Astrazeneca DATA QUALITY THROUGH STANDARDIZATION Philip Geronimo, Senior Education Director, VIASYS BIOMARKERS OF INFLAMMATION IN ASTHMA & COPD Theodore Reiss, Executive Director, Respiratory & Allergy, Merck Research Laboratories* LUNG FUNCTION PARAMETERS AND INTERPRETATION Dr Fred Bode, Associate Clinical Director, Medical Science, Hoffmann-La Roche - FEV1 remains in-sensitive to small airways changes
- Newer tests have high technical requirements
QUALITY CONTROL OF SPIROMETRY IN GLOBAL STUDIES Aleck Harrison, Consultant Clinical Scientist, AJH Partners - Over reading systems the plus and minus
- Identifying abnormalities and their cause
- Case studies
PATIENT REPORTED OUTCOMES AS COMPARED TO LUNG FUNCTION OUTCOMES Dr Göran Tornling, Vice President and Chief Medical Officer, Biolipox AB - Patient reported outcomes and lung function outcomes are not interchangeable
- Should exacerbations be defined from patient reported outcomes, lung function or intervention?
- The patient’s perspective
- The physician’s perspective
- The regulator’s perspective
CRTH2 A NOVEL TARGET FOR ASTHMA AND ALLERGY Mick Hunter, Director, Drug Discovery, Oxagen - Role of CRTH2 in allergy inflammation
- Oxagen CRTH2 antagonists
- Antagonists of CRTH2 as an approach to treat disease
- Clinical development status
USE OF CLINICAL ENDPOINTS OTHER THAN LUNG FUNCTION IN COPD CLINICAL STUDIES Dr Shahin Sanjar, Senior Director Respiratory Sciences, Altana Pharma - COPD is predominantly regarded as a chronic airway disease and so most clinical studies focus on measurement of lung function as a primary endpoint
- It is now recognized that COPD patients suffer co-morbidities such as CV, metabolic, GI and orthopaedic disease, which may be important contributors to the overall poor health status of patients
- Treatment of airway disease remains the gold standard for treating COPD. However, targeting the major co-morbidities may be critical in improving health status of COPD patients
- Persistent and/or latent pulmonary hypertension is recognized as a feature in many COPD patients, which can have a debilitating effect on physical activity in these patients
- Alternative clinical endpoints may be better predictors of disease progression in COPD
Chairman’s Closing Remarks and Close of Day One
Workshops
The Hatton, at etc. venues 24 April 2007 London, United Kingdom
copyright ©
2024
SAE Media Group
|